Drugs / CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product
CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07002112 | May 2025 → Jun 2027 expected | B-cell neoplasm | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07002112 ↗ |